bridgebio pharma - BBIO
BBIO
Close Chg Chg %
46.97 0.14 0.29%
Closed Market
47.10
+0.14 (0.29%)
Volume: 2.59M
Last Updated:
Jul 16, 2025, 4:00 PM EDT
Company Overview: bridgebio pharma - BBIO
BBIO Key Data
| Open $47.29 | Day Range 46.70 - 47.66 |
| 52 Week Range 21.72 - 48.68 | Market Cap $8.82B |
| Shares Outstanding 189.88M | Public Float 160.86M |
| Beta 1.15 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.53 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 3.46M |
BBIO Performance
| 1 Week | 1.07% | ||
| 1 Month | 12.54% | ||
| 3 Months | 38.66% | ||
| 1 Year | 79.32% | ||
| 5 Years | 48.95% |
BBIO Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
21
Full Ratings ➔
About bridgebio pharma - BBIO
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
BBIO At a Glance
BridgeBio Pharma, Inc.
3160 Porter Drive
Palo Alto, California 94304
| Phone | 1-650-391-9740 | Revenue | 221.90M | |
| Industry | Biotechnology | Net Income | -535,762,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 2,285.274% | |
| Fiscal Year-end | 12 / 2025 | Employees | 730 | |
| View SEC Filings |
BBIO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 23.01 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -11.631 |
| Enterprise Value to Sales | 29.945 |
| Total Debt to Enterprise Value | 0.333 |
BBIO Efficiency
| Revenue/Employee | 303,975.342 |
| Income Per Employee | -733,920.548 |
| Receivables Turnover | 46.993 |
| Total Asset Turnover | 0.303 |
BBIO Liquidity
| Current Ratio | 4.668 |
| Quick Ratio | 4.668 |
| Cash Ratio | 4.412 |
BBIO Profitability
| Gross Margin | 96.596 |
| Operating Margin | -260.191 |
| Pretax Margin | -244.339 |
| Net Margin | -241.441 |
| Return on Assets | -73.106 |
| Return on Equity | N/A |
| Return on Total Capital | -72.213 |
| Return on Invested Capital | -95.781 |
BBIO Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 297.853 |
| Total Debt to Total Assets | 240.371 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 297.227 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Bridgebio Pharma - BBIO
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 69.72M | 77.65M | 9.30M | 221.90M | |
Sales Growth
| +745.14% | +11.38% | -88.02% | +2,285.27% | |
Cost of Goods Sold (COGS) incl D&A
| 6.36M | 7.80M | 6.54M | 7.55M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 5.84M | 6.77M | 6.49M | 6.08M | |
Depreciation
| 3.24M | 4.37M | 4.09M | 3.67M | |
Amortization of Intangibles
| 2.60M | 2.40M | 2.40M | 2.40M | |
COGS Growth
| +105.86% | +22.78% | -16.21% | +15.49% | |
Gross Income
| 63.36M | 69.84M | 2.76M | 214.35M | |
Gross Income Growth
| +1,127.65% | +10.23% | -96.04% | +7,657.84% | |
Gross Profit Margin
| +90.88% | +89.95% | +29.70% | +96.60% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 639.99M | 538.28M | 602.21M | 791.72M | |
Research & Development
| 451.02M | 399.46M | 455.71M | 506.46M | |
Other SG&A
| 188.97M | 138.82M | 146.50M | 285.26M | |
SGA Growth
| +33.43% | -15.89% | +11.88% | +31.47% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (33.26M) | 55.72M | (1.72M) | 42.20M | |
EBIT after Unusual Expense
| (543.37M) | (524.15M) | (597.72M) | (619.56M) | |
Non Operating Income/Expense
| 3.70M | 119.94M | 25.76M | 176.66M | |
Non-Operating Interest Income
| 1.13M | 7.54M | 18.04M | 17.25M | |
Equity in Earnings of Affiliates
| - | - | - | (31.18M) | - |
Interest Expense
| 46.78M | 80.44M | 81.29M | 99.29M | |
Interest Expense Growth
| +27.62% | +71.96% | +1.06% | +22.14% | |
Gross Interest Expense
| 46.78M | 80.44M | 81.29M | 99.29M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (586.45M) | (484.65M) | (653.25M) | (542.19M) | |
Pretax Income Growth
| -16.02% | +17.36% | -34.79% | +17.00% | |
Pretax Margin
| -841.20% | -624.17% | -7,021.94% | -244.34% | |
Income Tax
| - | - | - | 1.15M | - |
Income Tax - Current - Domestic
| - | - | - | 811.00K | - |
Income Tax - Current - Foreign
| - | - | - | 342.00K | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | (31.18M) | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (586.45M) | (484.65M) | (653.25M) | (543.35M) | |
Minority Interest Expense
| (23.91M) | (3.47M) | (10.05M) | (7.58M) | |
Net Income
| (562.54M) | (481.18M) | (643.20M) | (535.76M) | |
Net Income Growth
| -25.36% | +14.46% | -33.67% | +16.70% | |
Net Margin Growth
| -806.90% | -619.70% | -6,913.92% | -241.44% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (562.54M) | (481.18M) | (643.20M) | (535.76M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (562.54M) | (481.18M) | (643.20M) | (535.76M) | |
EPS (Basic)
| -3.8969 | -3.2628 | -3.9511 | -2.8793 | |
EPS (Basic) Growth
| -2.47% | +16.27% | -21.10% | +27.13% | |
Basic Shares Outstanding
| 144.36M | 147.47M | 162.79M | 186.08M | |
EPS (Diluted)
| -3.8969 | -3.2628 | -3.9511 | -2.8793 | |
EPS (Diluted) Growth
| -2.47% | +16.27% | -21.10% | +27.13% | |
Diluted Shares Outstanding
| 144.36M | 147.47M | 162.79M | 186.08M | |
EBITDA
| (570.79M) | (461.67M) | (592.95M) | (571.29M) | |
EBITDA Growth
| -21.09% | +19.12% | -28.44% | +3.65% | |
EBITDA Margin
| -818.73% | -594.56% | -6,373.75% | -257.45% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 62.30 | |
| Number of Ratings | 21 | Current Quarters Estimate | -0.741 | |
| FY Report Date | 09 / 2025 | Current Year's Estimate | -2.824 | |
| Last Quarter’s Earnings | -0.734 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -2.88 | Next Fiscal Year Estimate | -1.634 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 17 | 17 | 18 | 19 |
| Mean Estimate | -0.74 | -0.67 | -2.82 | -1.63 |
| High Estimates | -0.09 | -0.27 | -1.12 | 1.99 |
| Low Estimate | -1.00 | -0.98 | -3.93 | -3.32 |
| Coefficient of Variance | -32.06 | -32.72 | -27.31 | -65.77 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 18 | 16 | 15 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 2 | 3 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Bridgebio Pharma - BBIO
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Bridgebio Pharma - BBIO
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 21, 2025 | Neil Kumar Chief Executive Officer; Director | 276,414 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Neil Kumar Chief Executive Officer; Director | 243,560 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $33.84 per share | 8,242,070.40 |
| May 21, 2025 | Neil Kumar Chief Executive Officer; Director | 217,804 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.32 per share | 7,257,229.28 |
| May 21, 2025 | Neil Kumar Chief Executive Officer; Director | 217,404 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.75 per share | 7,337,385.00 |
| May 21, 2025 | Neil Kumar Chief Executive Officer; Director | 4,798,447 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.4 per share | 160,268,129.80 |
| May 21, 2025 | Neil Kumar Chief Executive Officer; Director | 234,808 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Neil Kumar Chief Executive Officer; Director | 215,592 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Neil Kumar Chief Executive Officer; Director | 173,307 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Thomas Trimarchi President and CFO | 501,988 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $33.84 per share | 16,987,273.92 |
| May 21, 2025 | Maricel Apuli Chief Accounting Officer | 142,859 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $33.84 per share | 4,834,348.56 |
| Apr 4, 2025 | Andrea J. Ellis Director | 12,000 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34.05 per share | 408,600.00 |
| Apr 4, 2025 | Andrea J. Ellis Director | 42,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $8.45 per share | 354,900.00 |
| Apr 4, 2025 | Andrea J. Ellis Director | 74,921 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Hannah A. Valantine Director | 14,639 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16.75 per share | 245,203.25 |
| Mar 11, 2025 | Hannah A. Valantine Director | 1,764 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.58 per share | 57,471.12 |
| Mar 11, 2025 | Hannah A. Valantine Director | 38,626 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | Brian C. Stephenson CFO and Treasurer | 440,170 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 28, 2025 | Brian C. Stephenson CFO and Treasurer | 102,464 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34.18 per share | 3,502,219.52 |
| Feb 28, 2025 | Brian C. Stephenson CFO and Treasurer | 102,564 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.18 per share | 3,403,073.52 |
| Feb 28, 2025 | Brian C. Stephenson CFO and Treasurer | 110,964 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $17 per share | 1,886,388.00 |